Details

Autor(en) / Beteiligte

• Paris, Christophe
• Do, Pascal
• Mastroianni, Bénédicte
• Dixmier, Adrien
• Dumont, Patrick
• Pichon, Eric
• Chouaid, Christos
• Coudert, Bruno
• Foucher, Pascal
• Fraboulet, Séverine
• Locatelli-Sanchez, Myriam
• Baize, Nathalie
• Dansin, Eric
• Moreau, Lionel
• Vincent, Michel
• Missy, Pascale
• Morin, Franck
• Moro-Sibilot, Denis
• Couraud, Sébastien

Titel

Association between lung cancer somatic mutations and occupational exposure in never-smokers

Ist Teil von

• The European respiratory journal, 2017-10, Vol.50 (4), p.1700716-1700716

Ort / Verlag

England: European Respiratory Society Journals Ltd

Erscheinungsjahr

2017

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• Occupational exposure constitutes a common risk factor for lung cancer. We observed molecular alterations in 73% of never-smokers, 35% of men and 8% of women were exposed to at least one occupational carcinogen. We report herein associations between molecular patterns and occupational exposure.BioCAST was a cohort study of lung cancer in never-smokers that reported risk factor exposure and molecular patterns. Occupational exposure was assessed a validated 71-item questionnaire. Patients were categorised into groups that were unexposed and exposed to polycyclic aromatic hydrocarbons (PAH), asbestos, silica, diesel exhaust fumes (DEF), chrome and paints. Test results were recorded for and mutations, and alterations.Overall, 313 out of 384 patients included in BioCAST were analysed. Asbestos-exposed patients displayed a significantly lower rate of mutations (20% 44%, p=0.033), and a higher rate of mutations (18% 4%, p=0.084). alterations were not associated with any occupational carcinogens. The DEF-exposed patients were diagnosed with a mutation in 25% of all cases. Chrome-exposed patients exhibited enhanced and mutation frequency.Given its minimal effects in the subgroups, we conclude that occupational exposure slightly affects the molecular pattern of lung cancers in never-smokers. In particular, asbestos-exposed patients have a lower chance of mutations.